22211 West Interstate 10
Suite 1206
San Antonio, TX 78257
United States
210 698 5334
https://www.bioaffinitytech.com
Secteur(s): Healthcare
Secteur d’activité: Diagnostics & Research
Employés à temps plein:
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Steven Girgenti | Founder & Executive Chairman of the Board | 113,75k | S.O. | 1946 |
Ms. Maria Zannes J.D. | Founder, President, CEO & Director | 299,17k | S.O. | 1956 |
Mr. Michael Dougherty CPA, M.B.A. | VP & CFO | 238,92k | S.O. | 1979 |
Mr. Xavier T. Reveles M.S. | Chief Operating Officer | S.O. | S.O. | 1970 |
Dr. Vivienne I. Rebel M.D., Ph.D. | Executive VP and Chief Medical & Science Officer | 238,39k | S.O. | 1966 |
Mr. Timothy P. Zannes J.D. | Executive VP, Secretary & General Counsel | S.O. | S.O. | 1953 |
Ms. Julie Anne Overton | Director of Communications | S.O. | S.O. | S.O. |
Mr. Dallas J. Coleman | National Director of Sales | S.O. | S.O. | S.O. |
Dr. William Bauta Ph.D. | Senior Vice President of Therapeutics | S.O. | S.O. | S.O. |
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
L’ISS Governance QualityScore de bioAffinity Technologies, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..